| Annual · values | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -46000 USD | -8.00 M USD | -16.95 M USD | -18.71 M USD | -16.26 M USD | -13.11 M USD | -12.84 M USD | -10.03 M USD | -9.15 M USD | -7.92 M USD | -8.63 M USD | -3.85 M USD |
| Depreciation & Amortization | 0 USD | 161000 USD | 212000 USD | 404000 USD | 205000 USD | 148000 USD | 115000 USD | 147000 USD | 157000 USD | 130000 USD | 92000 USD | 78000 USD |
| Stock-Based Compensation | -12000 USD | 12000 USD | -57000 USD | 879000 USD | 491000 USD | 408000 USD | 516000 USD | -65000 USD | 726000 USD | 1.21 M USD | 3.72 M USD | 312000 USD |
| Capital Expenditures | — | — | 83000 USD | 486000 USD | 1.01 M USD | 379000 USD | 167000 USD | 94000 USD | 231000 USD | 166000 USD | 270000 USD | 46000 USD |
| Cash Flow from Investing | 48000 USD | -840000 USD | 21.36 M USD | -12.51 M USD | -16.01 M USD | -10.45 M USD | 5.45 M USD | -5.72 M USD | -231000 USD | 4.69 M USD | -5.07 M USD | -46000 USD |
| Cash Flow from Financing | — | — | — | 8.85 M USD | 51.02 M USD | 23.58 M USD | 6.51 M USD | 17.76 M USD | 4.58 M USD | 5.42 M USD | 22.01 M USD | — |
| Dividends Paid | — | — | — | — | — | — | — | — | — | — | — | — |
| Stock Buybacks | — | — | — | — | — | — | — | — | — | — | — | — |
| Free Cash Flow | — | — | -17.04 M USD | -19.19 M USD | -17.27 M USD | -13.49 M USD | -13.01 M USD | -10.13 M USD | -9.38 M USD | -8.09 M USD | -8.90 M USD | -3.90 M USD |
Check-Cap Ltd. is a clinical-stage medical diagnostics company based in Israel, specializing in the development of innovative capsule-based screening technology for colorectal cancer detection. Founded in 2004, the company focuses on its proprietary C-Scan system, which includes an ingestible capsule that uses ultra-low-dose X-rays to non-invasively scan the inner lining of the colon for precancerous polyps and structural abnormalities. This capsule-based approach aims to provide patient-friendly, preparation-free colorectal screening to increase adherence and enable early intervention. The system comprises the C-Scan capsule, a disposable tracking device attached externally to the patient, and analytic software for data processing and report generation. Check-Cap's technology represents a significant advancement in non-invasive cancer diagnostics, aligning with the broader healthcare sector's focus on early detection and preventive medicine.